Endoplasmin - Pipeline Review, H2 2019
Endoplasmin - Pipeline Review, H2 2019
SUMMARY
Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Endoplasmin - Pipeline Review, H2 2019, outlays comprehensive information on the Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Heat shock protein 90kDa beta member 1 (HSP90B1), known also as endoplasmin. It functions in the processing and transport of secreted proteins and endoplasmic reticulum associated degradation (ERAD). The molecules developed by companies in Phase II, Phase I, Discovery and Unknown stages are 2, 1, 1 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Glioblastoma Multiforme (GBM), Gliosarcoma, Hematological Tumor, Non-Small Cell Lung Cancer, Recurrent Glioblastoma Multiforme (GBM) and Solid Tumor.
Furthermore, this report also reviews key players involved in Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
SUMMARY
Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Endoplasmin - Pipeline Review, H2 2019, outlays comprehensive information on the Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Heat shock protein 90kDa beta member 1 (HSP90B1), known also as endoplasmin. It functions in the processing and transport of secreted proteins and endoplasmic reticulum associated degradation (ERAD). The molecules developed by companies in Phase II, Phase I, Discovery and Unknown stages are 2, 1, 1 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Glioblastoma Multiforme (GBM), Gliosarcoma, Hematological Tumor, Non-Small Cell Lung Cancer, Recurrent Glioblastoma Multiforme (GBM) and Solid Tumor.
Furthermore, this report also reviews key players involved in Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1)
- The report reviews Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Overview
Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Companies Involved in Therapeutics Development
Agenus Inc
Amgen Inc
Heat Biologics Inc
Spectrum Pharmaceuticals Inc
Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Drug Profiles
Fusion Protein to Target GRP94 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HS-130 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Panvotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit GRP94 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vitespen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Dormant Products
Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Product Development Milestones
Featured News & Press Releases
Dec 16, 2019: Heat Biologics announces first patient dosed in the first phase 1 trial of HS-130
Aug 12, 2019: Heat Biologics announces FDA clearance of IND application to begin phase 1 trial of HS-130 in combination with Heat’s HS-110
Apr 02, 2019: Heat Biologics delivers poster presentation at the AACR Annual Meeting 2019
Jun 01, 2015: Updated Phase 2 Data of Prophage In Newly Diagnosed GBM Presented at ASCO
May 14, 2015: Agenus Announces Oral Presentation at ASCO Highlighting Improved Survival with Prophage Immunotherapy in Brain Cancer Compared to Historical Controls
Jul 01, 2014: Agenus Brain Cancer Vaccine Shows Extended Survival in Phase 2 Final Data Analysis
Jan 21, 2014: Agenus’ Prophage Vaccine for Glioma Hailed As a ‘Very Promising Therapy’ in an Editorial Published in the Journal Neuro-Oncology
Dec 16, 2013: Positive Phase 2 Results from Agenus’ Brain Cancer Vaccine Published in Neuro-Oncology
Sep 17, 2013: Agenus Reports Positive Follow-on Phase 2 Results for Brain Cancer Vaccine in Newly Diagnosed Patients
May 22, 2013: Agenus Announces Initiation Of Enrollment In NCI-sponsored Randomized Trial Of Prophage G-200 Vaccine With Avastin In Treatment Of Brain Tumors
May 01, 2013: Agenus Announces Presentation Of Preliminary Data From Phase II Clinical Trial Of Brain Cancer Vaccine At AANS Meeting
Apr 10, 2013: Agenus Presents Brain Cancer Vaccine Results At 81st AANS Annual Scientific Meeting 2013
Aug 08, 2012: Agenus Announces Publication Of Key Data Showing Antitumor Activity Of Prophage Vaccine In Clinical Cancer Research
Apr 17, 2012: Agenus Presents New Phase II Data From Brain Cancer Study Of Prophage Vaccine At Plenary Session Of AANS
Apr 17, 2012: NCI Group Selects HSPPC-96 Vaccine For Randomized Large-Scale Study With Bevacizumab For Recurrent Glioblastoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Overview
Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Companies Involved in Therapeutics Development
Agenus Inc
Amgen Inc
Heat Biologics Inc
Spectrum Pharmaceuticals Inc
Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Drug Profiles
Fusion Protein to Target GRP94 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HS-130 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Panvotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit GRP94 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vitespen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Dormant Products
Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Product Development Milestones
Featured News & Press Releases
Dec 16, 2019: Heat Biologics announces first patient dosed in the first phase 1 trial of HS-130
Aug 12, 2019: Heat Biologics announces FDA clearance of IND application to begin phase 1 trial of HS-130 in combination with Heat’s HS-110
Apr 02, 2019: Heat Biologics delivers poster presentation at the AACR Annual Meeting 2019
Jun 01, 2015: Updated Phase 2 Data of Prophage In Newly Diagnosed GBM Presented at ASCO
May 14, 2015: Agenus Announces Oral Presentation at ASCO Highlighting Improved Survival with Prophage Immunotherapy in Brain Cancer Compared to Historical Controls
Jul 01, 2014: Agenus Brain Cancer Vaccine Shows Extended Survival in Phase 2 Final Data Analysis
Jan 21, 2014: Agenus’ Prophage Vaccine for Glioma Hailed As a ‘Very Promising Therapy’ in an Editorial Published in the Journal Neuro-Oncology
Dec 16, 2013: Positive Phase 2 Results from Agenus’ Brain Cancer Vaccine Published in Neuro-Oncology
Sep 17, 2013: Agenus Reports Positive Follow-on Phase 2 Results for Brain Cancer Vaccine in Newly Diagnosed Patients
May 22, 2013: Agenus Announces Initiation Of Enrollment In NCI-sponsored Randomized Trial Of Prophage G-200 Vaccine With Avastin In Treatment Of Brain Tumors
May 01, 2013: Agenus Announces Presentation Of Preliminary Data From Phase II Clinical Trial Of Brain Cancer Vaccine At AANS Meeting
Apr 10, 2013: Agenus Presents Brain Cancer Vaccine Results At 81st AANS Annual Scientific Meeting 2013
Aug 08, 2012: Agenus Announces Publication Of Key Data Showing Antitumor Activity Of Prophage Vaccine In Clinical Cancer Research
Apr 17, 2012: Agenus Presents New Phase II Data From Brain Cancer Study Of Prophage Vaccine At Plenary Session Of AANS
Apr 17, 2012: NCI Group Selects HSPPC-96 Vaccine For Randomized Large-Scale Study With Bevacizumab For Recurrent Glioblastoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Agenus Inc, H2 2019
Pipeline by Amgen Inc, H2 2019
Pipeline by Heat Biologics Inc, H2 2019
Pipeline by Spectrum Pharmaceuticals Inc, H2 2019
Dormant Projects, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Agenus Inc, H2 2019
Pipeline by Amgen Inc, H2 2019
Pipeline by Heat Biologics Inc, H2 2019
Pipeline by Spectrum Pharmaceuticals Inc, H2 2019
Dormant Projects, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Agenus Inc
Amgen Inc
Heat Biologics Inc
Spectrum Pharmaceuticals Inc
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Agenus Inc
Amgen Inc
Heat Biologics Inc
Spectrum Pharmaceuticals Inc
